| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803032001025 | 303200102 | ZOLMEMIN F.C.TAB 10MG/TAB BTx28 (BLIST. 4x7) σε PVC/PVDC | 8.30 | 8.71 | 12.00 |
| 05/2018 | 2803032001032 | 303200103 | ZOLMEMIN F.C.TAB 10MG/TAB BTx30 (BLIST. 3x10) σε PVC/PVDC | 8.89 | 9.33 | 12.86 |
| 05/2018 | 2803032001193 | 303200119 | ZOLMEMIN F.C.TAB 10MG/TAB BTx28 (BLIST. 4x7) σε ALU/ALU | 8.30 | 8.71 | 12.00 |
| 05/2018 | 2803032001209 | 303200120 | ZOLMEMIN F.C.TAB 10MG/TAB BTx30 (BLIST. 3x10) σε ALU/ALU | 8.89 | 9.33 | 12.86 |
| 05/2018 | 2803032002022 | 303200202 | ZOLMEMIN F.C.TAB 20MG/TAB BTx28 (BLIST. 4x7) σε PVC/PVDC | 14.62 | 15.34 | 21.14 |
| 05/2018 | 2803032002152 | 303200215 | ZOLMEMIN F.C.TAB 20MG/TAB BTx28 (BLIST. 4x7) σε ALU/ALU | 14.62 | 15.34 | 21.14 |
| 05/2018 | 2803032004019 | 303200401 | ZOLMEMIN ORAL.SOL 5MG/ενεργοποίηση αντλίας (Pump actuation) Φιαλίδιο x 50ml | 13.55 | 14.21 | 19.58 |
For the treatment of moderate to severe dementia of the Alzheimer's type.
Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg<sup>2+</sup> ions and allow continuous influx of Ca<sup>2+</sup> ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg<sup>2+</sup> ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca<sup>2+</sup> ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT<sub>3</sub>) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for γ-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.
Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
60-100 hours
Memantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. It is excreted predominantly in the urine, unchanged.
* 9 to 11 L/kg